GLPwatch

Obesity and diabetes: the final frontier.

Expert Rev Endocrinol Metab · 2023

Last updated 2026-05-28

A review of obesity treatment options highlights that GLP-1 receptor agonists like semaglutide and tirzepatide have become leading medications for weight loss, with long-term results approaching the effectiveness of bariatric surgery. The review also notes that these drugs work by affecting brain satiety centers to reduce food intake, offering a non-invasive alternative to surgery for people with or without diabetes.

AI summary of the abstract below.

JournalExpert Rev Endocrinol Metab, 2023
Citations11
Relative citation ratio1.58
NIH percentile66
Molecules
Conditions studied Type 2 Diabetes, Obesity

Abstract

INTRODUCTION: Obesity is a key target in the treatment and prevention of diabetes and independently to reduce the burden of cardiovascular disease. We reviewed the options now available and anticipated to deal with obesity. AREAS COVERED: We considered the epidemiology, genetics, and causation of obesity and the relationship to diabetes, and the dietary, pharmaceutical, and surgical management of the condition. The literature search covered both popular media via Google Search and the academic literature as indexed on PubMed with search terms including obesity, childhood obesity, adipocytes, insulin resistance, mechanisms of satiety, bariatric surgery, GLP-1 receptor agonists, and SGLT2 inhibitors. EXPERT OPINION: Although bariatric surgery has been the primary approach to treating obese individuals, the emergence of agents impacting the brain satiety centers now promises effective, non-invasive treatment of obesity for individuals with and without diabetes. The GLP-1 receptor agonists have assumed the primary role in treating obesity with significant weight loss. Long-term results with semaglutide and tirzepatide are now approaching the success seen with bariatric surgery. Future agents combining the benefits of satiety control and thermogenesis to dissipate caloric excess are under investigation.

Verbatim abstract via PubMed 36710450 ↗